N/A
N=29
Calcium Absorption in Patients With Rothmund-Thomson Syndrome
Rothmund-Thomson Syndrome
Bottom Line
View on ClinicalTrials.gov: NCT01304407 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Jul 2020
Primary outcome: Primary: Bone Density (Low Areal Bone Mineral Density (aBMD)) — -1.3; -0.9; -2.4; -1.2 z-score
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Calcium stable isotope (Other)
- Age
- Pediatric, Adult, Older Adult · 4+ yrs
- Sex
- All
- Sponsor
- Baylor College of Medicine
- Primary completion
- Oct 2015
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Bone Density (Low Areal Bone Mineral Density (aBMD)) |
-1.3; -0.9; -2.4; -1.2; -2.4; -0.8 | — |
Summary
Osteosarcoma is the most common malignant bone tumor in children and adolescents. Because cure rates for osteosarcoma have remained stagnant for the past several decades despite numerous trials of chemotherapy agents, novel therapies based on the understanding of the molecular pathogenesis of osteosarcoma are needed. Rothmund-Thomson Syndrome (RTS) is a genetic disorder affecting many parts of the body and resulting in major skeletal abnormalities. This disease also has the propensity to increase the risk of developing cancer, particularly osteosarcoma. Two-thirds of RTS patients have a high risk of developing osteosarcoma. Therefore, it is important to understand the impact of RTS on the skeletal phenotype (as measured by bone density) in order to develop effective therapies to battle osteosarcoma.
Eligibility Criteria
Inclusion Criteria
- Patients at least four years of age who have been diagnosed clinically with RTS by a physician.
Exclusion Criteria
- Any person who does not meet the inclusion criteria.
Data sourced from ClinicalTrials.gov (NCT01304407). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.